Tecentriq, Kesimpta lead latest SMC decisions

13th July 2021 Uncategorised 0

SMC was unable to accept Pfizer’s Vyndaqel for use in patients with transthyretin amyloidosis

More: Tecentriq, Kesimpta lead latest SMC decisions
Source: News